Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Achondroplasia

Connective Tissue & Musculoskeletal

Achondroplasia Clinical Trials and Treatments

Also called Short-Limbed Dwarfism, Achondroplastic Dwarfism, Chondrodystrophy

Achondroplasia is caused by a gain-of-function mutation in the FGFR3 gene on chromosome 4, which encodes a receptor that normally limits bone growth. Nearly all cases (over 97%) involve the same specific mutation (G380R), making it one of the most genetically uniform rare diseases. The overactive FGFR3 receptor suppresses growth plate activity in the long bones, leading to shortened limbs while the trunk grows to near-normal size.

In plain words, achondroplasia is the most common form of short-limbed dwarfism, caused by a change in a gene that controls bone growth. Growth of the long bones slows, so the arms and legs stay short while the body's trunk is close to average size.

Get an email when new Achondroplasia trials open or the FDA decides. Get alerts

Achondroplasia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 5 studies with no phase, like observational studies.

FDA review3

Infigratinib, Feb 4, 2027 · Voxzogo, Feb 28, 2027 · Voxzogo, May 30, 2027

FDA-approved medicines2

Yuviwel · Voxzogo

Achondroplasia has 2 FDA-approved medicines, 11 open or active clinical trials (9 recruiting), and a pending FDA decision on Infigratinib, due Feb 4, 2027.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Each date is the day a change was posted. Open an item to see where things stand now.

More about Achondroplasia

Beyond short stature, achondroplasia causes significant medical complications that require lifelong monitoring. Foramen magnum stenosis (narrowing at the base of the skull) is a serious concern in infancy that can compress the brainstem and spinal cord. Spinal stenosis develops in most adults and is the leading cause of pain and disability. Sleep apnea from midface hypoplasia affects a large proportion of children and adults.

Keep reading about Achondroplasia

Hydrocephalus, recurrent ear infections, and obesity are additional concerns. In 2021, the FDA approved Voxzogo (vosoritide), a C-type natriuretic peptide analog developed by BioMarin that counteracts the overactive FGFR3 signaling to promote bone growth in children with open growth plates. This was the first drug approved specifically for achondroplasia.

What are the symptoms of Achondroplasia?

These are common symptoms of Achondroplasia, and how strong they are varies from person to person.

  • Short stature with disproportionately short arms and legs, especially upper arms and thighs
  • Large head (macrocephaly) with prominent forehead and flattened nasal bridge
  • Limited elbow extension and reduced range of motion at multiple joints
  • Bowed legs (genu varum) that worsen with walking
  • Exaggerated lower back curve (lumbar lordosis) with prominent abdomen
  • Spinal stenosis causing back pain, leg weakness, and numbness in adulthood
  • Obstructive sleep apnea from midface underdevelopment
  • Recurrent middle ear infections and conductive hearing loss in childhood
  • Delayed motor milestones, with walking typically starting at 18 to 24 months
  • Dental crowding from smaller jaw size

Who gets Achondroplasia?

Achondroplasia is present from birth and affects males and females equally across all racial and ethnic groups. About 80% of cases are de novo mutations in parents of average height, with a strong association with advanced paternal age.

The remaining 20% are inherited from an affected parent in an autosomal dominant pattern. Average adult height is approximately 4 feet 4 inches for males and 4 feet 1 inch for females.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Achondroplasia?

There are currently 2 FDA-approved medications for Achondroplasia.

navepegritide
Ascendis Pharma
Search
vosoritide

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Achondroplasia medicines are in trials?

Investigational medicines Trial Friend tracks for Achondroplasia, with trial results, safety findings and where each one stands.

How to get help paying for Achondroplasia treatment

Charity funds and drugmaker programs for Achondroplasia, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Little People of America
    Grant for Overall Accessible Living (GOAL) fund
    Open

    Pays for: Mobility devices and occupational tools (partial cost; LPA membership required).

    The foundation says: “Applications are being accepted for the GOAL Fund.”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Achondroplasia, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Achondroplasia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Achondroplasia resources

Reputable organizations and medical references for learning more about Achondroplasia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Achondroplasia

Use this Achondroplasia clinical trial finder to see the 9 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 6 test a treatment and 5 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Infigratinib, due February 4, 2027; Voxzogo (vosoritide), due February 28, 2027; Voxzogo (vosoritide), due May 30, 2027. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

11 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 2Recently updatedNCT06842355

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Intervention: TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg, TYRA-300 0.50 mg/kg, TYRA-300 0.625 mg/kg

Sponsor: Tyra Biosciences, Inc

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Ages 3 Years to 10 Years
Started Mar 2025Updated 3 days agoEst. Jan 2030 (~3y 2m)
RecruitingObservational study, no treatment givenRecently updatedNCT07388966

Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia

Sponsor: SYSNAV

The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history study to measure limb movements in patients with ACH or HCH.

Ages 2 Years to 65 Years4 locations
Started Feb 2026Updated 4 days agoEst. Dec 2028 (~2y 1m)
Not yet recruitingTreatment trialPhase 3Recently updatedNCT07924059

Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia

Intervention: Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide

Sponsor: Ascendis Pharma A/S

This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.

Ages 2 Years to 17 Years
Expected to start Nov 2026Updated 1 week agoEst. Sep 2028 (~1y 10m)
RecruitingTreatment trialPhase 2/3Recently updatedNCT07441876

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Intervention: BMN 333, Vosoritide Injection [Voxzogo]

Sponsor: BioMarin Pharmaceutical

This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.

Ages 2 Years to 17 Years
Started Apr 2026Updated 1 month agoEst. Jun 2029 (~2y 7m)
RecruitingTreatment trialPhase 2Updated a few months agoNCT07169279

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Intervention: Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration

Sponsor: QED Therapeutics, a BridgeBio company

This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants < 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Pha...

Ages 0 Years to 32 Months
Started Nov 2025Updated 4 months agoEst. Mar 2030 (~3y 4m)
Find Achondroplasia trials near you, ranked by distance →
Active trial locations21 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+13 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Achondroplasia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an Achondroplasia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Achondroplasia patient communities

Facebook groups, Reddit communities and YouTube channels where Achondroplasia patients, caregivers and advocacy groups talk.

Achondroplasia news and guides

Trial Friend articles about Achondroplasia, newest first

Companies developing Achondroplasia treatments

Drugmakers that list Achondroplasia in their rare disease portfolio, 5 in all.

Questions people ask about Achondroplasia